Dr. Concin on the Rationale for the LIO-1 Trial in Advanced Gynecologic Malignancies

Nicole Concin, MD, professor, experimental gynecology, Department of Gynecology and Obstetrics, Medical University of Innsbruck, Innsbruck, Austria, discusses the rationale for the ​phase 1/2 LIO-1 trial in advanced gynecologic malignancies.

The phase 2 portion of the LIO-1 trial will evaluate the safety and efficacy of lucitanib, an investigational ​and potent TKI that inhibits VEGFR 1-3, PDGFRα/β, and FGFR 1-3, in combination with nivolumab (Opdivo) in patients with advanced ​gynecologic solid tumors, says Concin.

Notably, the rationale to combine angiogenesis inhibitors with immunotherapy is based on preclinical data that demonstrated increased efficacy with this approach, Concin concludes.